A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
Stopped early · Phase 1
Conditions studied: Advanced Non-Hematologic Malignancies
In brief
Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive to standard therapies.
Key facts
- Study ID
- NCT00915278
- Run by
- Pfizer
- People needed
- 33
- Starts
- 2009-09-01
- Expected to finish
- 2013-01-01
- Last updated by the study team
- 2014-04-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed advanced measurable or evaluable solid tumors unresponsive to currently available therapies, or for which there is no curative therapy
- Eastern Cooperative Oncology Group (ECOG) performance status 0 and 1
- Life expectancy more than12 weeks
- Adequate bone marrow, liver and renal function
You may not qualify if…
- Known brain metastasis
- Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of start of screening procedures
- Major surgical procedure within 4 weeks of start of screening procedures
- Active bleeding disorder, including gastrointestinal bleeding, as evidenced by hematemesis, significant hemoptysis or melena in the past 6 months
Where it is running
- Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
- Pfizer Investigational Site — Nashville, Tennessee, United States
- Pfizer Investigational Site — Nashville, Tennessee, United States
- Pfizer Investigational Site — Nashville, Tennessee, United States
- Pfizer Investigational Site — Tooting, London, United Kingdom
- Pfizer Investigational Site — North Cheam, Surrey, United Kingdom
- Pfizer Investigational Site — Sutton, Surrey, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.